Standout Papers

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease 2020 2026 2022 2024276
  1. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease (2020)
    Shorena Janelidze, Erik Stomrud et al. Nature Communications

Immediate Impact

2 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
2025 Standout
Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
2024 Standout
9 intermediate papers

Works of Randy Slemmon being referenced

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
2021
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
2020 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Randy Slemmon 396 237 100 137 15 500
C M Hulette 334 199 49 151 10 528
Peter Seubert 366 191 52 136 9 441
Priya Singhal 304 98 138 122 14 520
Hiroshi Shimadzu 278 85 72 137 17 442
Valerie Guss 341 86 130 200 14 545
Wang‐Sheng Jin 279 101 47 130 21 469
Isabel Hernández 245 173 42 125 21 439
V. Haroutunian 208 118 69 139 8 421
Katharina Buch 314 246 38 126 14 521
J.J. Hauw 321 129 66 155 17 493

All Works

Loading papers...

Rankless by CCL
2026